Search Results - "Benito Ibarrondo, Begoña"

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY by Palomares, Laida Cuevas, Pérez, Ernesto, Cilaurren, Ariane Unamunzaga, De Ocariz, Xabier Gutierrez Lopez, Ureña, Buenaventura Buendia, Fernández, Carmen Molinillo, Ibarrondo, Begoña Benito, Osua, Ana Cordero, Delgado, Beatriz Benitez, Moralejo, Miguel Andrés, Albás, Juan García, Castro, Jose Guinea

Get full text

Ultrafast 30-min infusion of a rituximab biosimilar (Truxima) by Pérez-Persona, Ernesto, Cuevas Palomares, Laida, Unamunzaga Cilaurren, Ariane, Gutiérrez López de Ocáriz, Xabier, Buendía Ureña, Buenaventura, Vega González de Viñaspre, Ana, Benito Ibarrondo, Begoña, Molinillo Fernández, María Carmen, Cordero Osúa, Ana, Benítez Delgado, Beatriz, García Albás, Juan José, Andrés Moralejo, Miguel Ángel, Guinea de Castro, José María

“…In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for…”
Get full text

Txagorrapid: Ultrarapid infusion in 30 minutes of the biosimilar of rituximab truxima—A cohort study by Perez Persona, Ernesto, Cuevas Palomares, Laida, Unamunzaga Cilaurren, Ariane, Gutierrez López de Gutierrez, Xabier, Buendía Ureña, Buenaventura, Molinillo Fernández, Carmen Luisa, Benito Ibarrondo, Begoña, Cordero Osua, Ana Isabel, Benítez Delgado, Beatriz, Andrés Moralejo, Miguel Angel, García Albás, Juan José, Guinea de Castro, José María

“…e13638 Background: Rituximab (anti-CD20 Ab) is the cornerstone of the treatment of non-Hodgkin B lymphomas. Infusion-related reactions (IRR) are the most…”
Get full text